Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

Stone, Gregg W.; Witzenbichler, Bernhard; Weisz, Giora; Rinaldi, Michael; Neumann, Franz Josef; Metzger, D. Christopher; Henry, Timothy D.; Cox, David A.; Duffy, Peter L.; Mazzaferri, Ernest L.; Gurbel, Paul A.; Xu, Ke; Parise, Helen; Kirtane, Ajay J.; Brodie, Bruce R.; Mehran, Roxana; Stuckey, Thomas

doi:10.1016/s0140-6736(13)61170-8

Cited by 776 publications

(629 citation statements)

References 31 publications

Supporting

Mentioning

556

Contrasting

Unclassified

Order By: Relevance

“…We analyzed data from the CHARM program [13] , the ADAPT-DES study [14] , the THIN study [15] , and the PROMETHEUS study [16] . For each dataset, we focused on one "treatment" comparison and one outcome of prime interest.…”

Section: Datasetsmentioning

confidence: 99%

“…The overall goal was to produce relevant PS models across a range of different settings, so for some cases these choices differed from the primary objectives of the original publications. The terms "treatment" and "control" are used -5 -throughout to simplify the language even though one study [14] performed comparisons for platelet reactivity. All outcomes studied were time-to-event with censoring occurring at the end of planned follow-up or at the time of patient withdrawal or lost to follow-up.…”

Section: Datasetsmentioning

confidence: 99%

“…The ADAPT-DES study [14] investigated the relationship between high platelet reactivity (HPR) on clopidogrel (HPR 4,930 patients, not HPR 3,650 patients) to stent thrombosis and other cardiovascular events at 12 months follow-up in a prospective, multicentre registry of patients receiving drug-eluting stents. Herein we focus on stent thrombosis (56 events).…”

Section: Datasetsmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of Propensity Score Methods and Covariate Adjustment

Elze

Gregson

Baber

et al. 2017

Journal of the American College of Cardiology

Self Cite

513

392

View full text Add to dashboard Cite

Abstract:Propensity scores (PS) are an increasingly popular method to adjust for confounding in observational studies. PS methods have theoretical advantages over traditional covariate adjustment, but their relative performance in real-word scenarios is poorly characterized. We used datasets from four large-scale cardiovascular observational studies (PROMETHEUS, ADAPT-DES, THIN, and CHARM) to compare the performance of traditional covariate adjustment and four commonly used PS methods: matching, stratification, inverse probability weighting and use of propensity score as a covariate. We found that stratification performed poorly with few outcome events, and inverse probability weighting gave imprecise estimates of treatment effect and undue influence to a small number of observations when substantial confounding was present. Covariate adjustment and matching performed well in all of our examples, although matching tended to give less precise estimates in some cases. PS methods are not necessarily superior to traditional covariate adjustment, and care should be taken to select the most suitable method.

show abstract

Section: Datasetsmentioning

confidence: 99%

Section: Datasetsmentioning

confidence: 99%

Section: Datasetsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Propensity Score Methods and Covariate Adjustment

Elze

Gregson

Baber

et al. 2017

Journal of the American College of Cardiology

Self Cite

513

392

View full text Add to dashboard Cite

show abstract

“…Although high on‐clopidogrel platelet reactivity is prevalent and associated with a higher risk of recurrent ischemic events,28, 29, 30 and several studies have shown that switching between P2Y 12 inhibitors is safe and effectively reduces platelet reactivity in patients with high on‐clopidogrel platelet reactivity,31 no randomized controlled trial has demonstrated that intensifying P2Y 12 inhibition reduces clinical end points in patients with high on‐clopidogrel platelet reactivity 12, 13, 14, 15, 16. Platelet function testing is infrequently performed in current practice,15 and recurrent ischemic events while taking clopidogrel may not necessarily reflect inadequate platelet inhibition.…”

Section: Discussionmentioning

confidence: 99%

Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE‐ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study

Kaltenbach

Peterson

Akhter

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundGuidelines recommend P2Y12 inhibitor therapy for 1 year after myocardial infarction (MI), yet little guidance is provided on antiplatelet management for patients with recurrent ischemic events during that year. We describe changes in P2Y12 inhibitor type among patients with recurrent ischemic events in the first year after MI.Methods and ResultsThe TRANSLATE‐ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) study enrolled 12 365 patients with MI treated with percutaneous coronary intervention. We examined whether P2Y12 inhibitor choice changed among patients with recurrent MI, stent thrombosis, and/or unplanned revascularization during the first year after MI, and modeled factors associated with P2Y12 inhibitor intensification (changing clopidogrel to prasugrel or ticagrelor). In the first year after MI, 1414 patients (11%) had a total of 1740 recurrent ischemic events (771 recurrent MIs, 969 unplanned revascularizations, and 165 stent thromboses). Median time to the first recurrent ischemic event was 154 days (25th–75th percentiles, 55–287 days). Of those with recurrent ischemic events, 101 of 1092 (9.3%) occurring in clopidogrel‐treated patients led to P2Y12 inhibitor intensification. Recurrent events involving stent thrombosis or MI were the strongest factors associated with P2Y12 inhibitor intensification, yet only 40% of patients with stent thrombosis and 14% of patients with recurrent MI had P2Y12 inhibitor intensification. Increasing age and longer time from the index MI were associated with lower likelihood for intensification.ConclusionsFew patients after MI with a recurrent ischemic event who were taking clopidogrel switched to a more potent P2Y12 inhibitor, even after stent thrombosis events. Specific guidance is needed for patients who have recurrent ischemic events, particularly when closely spaced.Clinical Trial RegistrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT01088503.

show abstract

“…Наблюдение за больными с ВОРТ показало, что этот признак имеет неблагоприятное про-гностическое значение (табл.) [3][4][5][6][7][8][9][10][11][12][13][14]. ВОРТ может рассматриваться как модифицируемый фактор риска ИБС с неблагоприятным про-гностическим значением.…”

unclassified

Individual Approach to Patients With Indication for Antiplatelet Therapy. What to Rely on in Choosing the Therapy?

Lomakin¹,

Сумароков²,

Доценко³

et al. 2017

Aterotromboz

View full text Add to dashboard Cite

Н акопленный опыт применения антиаг-регантной терапии у больных ИБС поз-волил сформулировать некоторые крае-угольные положения лечения препаратами дан-ного ряда. Во-первых, антиагреганты, безуслов-но, нужны и полезны при лечении ИБС.Прежде всего, это четко видно у больных ОКС и после имплантации коронарного стен-та, где их широкое внедрение позволило зна-чительно улучшить исходы болезни. Во-вто-рых, назначая антиагрегант или комбинацию препаратов этого класса, врач должен предви-деть возможности как чрезмерной выражен-ности антитромботического эффекта, так и недостаточной степени его эффекта, несмотря на регулярный прием и адекватные дозы пре-парата; последнее явление получило название «резистентность к антиагреганту». Оба откло-нения могут привести к серьезным клиничес-ким осложнениям -к кровотечению или, на-оборот, к тромбозу. В недостаточном эффекте препарата могут быть виноваты и генетически обусловленные нарушения метаболизма от-дельных препаратов на уровне цитохромов

show abstract

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

Cited by 776 publications

References 31 publications

Comparison of Propensity Score Methods and Covariate Adjustment

Comparison of Propensity Score Methods and Covariate Adjustment

Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE‐ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study

Individual Approach to Patients With Indication for Antiplatelet Therapy. What to Rely on in Choosing the Therapy?

Contact Info

Product

Resources

About